IMPORTANCE Given evidence of overdiagnosis and overtreatment of small papillary thyroid cancers (PTCs), strategies are needed to promote the consideration of less invasive treatment options for patients with low-risk PTC.
O veruse of medical services, which encompasses overdiagnosis and overtreatment, is now recognized as a health risk. 1 In the context of prostate cancer and breast cancer, evidence has emerged that the push for early detection by screening asymptomatic men and women can lead to detection and treatment of cancers that may never have caused harm. [2] [3] [4] More recently, evidence has emerged of a "worldwide epidemic of thyroid cancer," 5 with studies indicating overdiagnosis of small papillary thyroid cancers (PTCs) as being the main driver of the increased incidence. 6, 7 Widespread access to health services as well as technological advances in diagnostic imaging and screening have likely led to the detection of a reservoir of indolent PTCs. 8, 9 Total surgical removal of the thyroid (thyroidectomy) and partial surgical removal of the thyroid (hemithyroidectomy) are the most common management approaches for patients with PTC, yet these surgical procedures are associated with a degree of serious risk, 10,11 the potential need for lifelong thyroid replacement medication, 12,13 and anxiety. 14,15 Less invasive treatment options have garnered support in light of the suggestion of overdiagnosis of PTC and evidence from active surveillance studies. [16] [17] [18] These studies demonstrate that rates of metastases-progression to clinical disease and growth of the tumor-in patients with small PTC who receive immediate surgery are comparable to the rates in those who are under active surveillance management.
19-21
Recommendations for active surveillance now exist, but a recent qualitative study suggests most clinicians prefer to manage small PTCs surgically. 22 Therefore, at this time, most patients with a PTC diagnosis are immediately recommended for and proceed to surgery, making it difficult for patients to consider and follow an active surveillance plan.
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Strategies are needed to promote the consideration of less invasive treatment options for PTCs and other indolent lesions with low malignant potential. 24 One such strategy is changing the terminology of low-risk PTC to exclude the term cancer. This change has been proposed and tested for ductal carcinoma in situ (DCIS)-a condition also known for low-risk lesions that are unlikely to cause harm if left untreated-to reduce the anxiety and shift the preferences of both clinicians and patients away from unnecessary aggressive treatments. 25, 26 A similar change to PTC terminology has been suggested 6 ; however, no evidence has yet emerged to show how a change in PTC nomenclature may affect treatment preferences. Taking into account the evidence of overdiagnosis and possible overtreatment of small PTCs and the appropriateness of following an active surveillance management plan, we conducted a randomized study to determine the association between treatment preferences and anxiety levels for PTC and the terminology used to describe the condition (with and without the term cancer).
Methods
The University of Sydney Human Research Ethics Committee approved this study. Verbal consent was initially obtained via telephone by the research company that sent the online link to each study participant before their participation. Further consent was implied as the participant began and completed the online study. The trial protocol is available in Supplement 1.
Design
Between March 16, 2016, and July 26, 2016, an online study was conducted among a random community sample (N = 550) ( Table 1) . Based on the study by Omer et al, 27 which tested the association of DCIS terminology with treatment preferences, the online study presented participants with 3 clinical scenarios of a PTC diagnosis using the terminologies papillary thyroid cancer, papillary lesion, and abnormal cells. These scenarios were designed to be typical real-life clinical scenarios and were developed and revised with input from our study team's thyroid cancer expert (J. P. B.) as well as consumer collaborators. Each scenario was identical except for the terminology used to describe the diagnosis and asked participants to choose among the 3 treatment options (total thyroidectomy, hemithyroidectomy, or active surveillance) to manage their hypothetical PTC diagnosis. The study specifically indicated to participants that each diagnosis was different but the 3 treatment options and their associated risks and advantages were the same. The study followed a randomized crossover design, whereby participants were randomly assigned by scenario ordering to ensure an equal distribution of the 6 different terminology sequences; approximately one-third of participants were randomized to see 1 
Participants and Procedures
Participants included 550 Australian men and women who were 18 years or older and spoke adequate English. Individuals were ineligible to participate if they had a history of thyroid cancer or had no email address given that the study was sent by email directly to eligible participants. In total, 606 participants began the study and were randomized. However, 56 participants (9.2%) did not complete the entire study, leaving 550 participants (90.8%) included in the analysis. Fifty-five individuals (9.0%) were lost to follow-up after randomization. The study was administered by the Hunter Research Foundation (HRF), an independent research organization. The HRF used mobile random-digit dialing across Australia to contact potential participants from a community sample. Once the HRF obtained a verbal agreement from a participant, the HRF emailed an online link to the study along with the Participant Information Sheet to the participant. Participants were able to access and complete the study in their own time. To ensure adequate randomization and minimize the number lost to follow-up, we randomized participants only if they began the study. Participants who did not initially respond to the study received 3 reminders (2 emails and 1 text message) that included a link to the study. The median (range) time it took to complete the study was 11 (2-58) minutes. No incentives were provided to participants. The participant flow is shown in the Figure. Researchers conducted a pilot of the study with a convenience sample of 12 adults, and the HRF subsequently conducted a pilot with a community sample of 30 adults. We made minor changes to the study on the basis of the feedback collected from the 2 pilots before the HRF formally administered the final study.
Outcome Measures
The primary outcomes were treatment choice, diagnosis anxiety, and treatment choice anxiety. Treatment choice was measured as a direct choice among total thyroidectomy, hemithyroidectomy, or active surveillance. Diagnosis anxiety and treatment choice anxiety were measured on a Visual Analog Scale with anchored end points ranging from "not anxious at all" to "extremely anxious." 30 Because the study was online, participants were able to move a cursor along the scale and place it at 1 of 11 points between "not anxious at all" to "extremely anxious." All primary outcomes were measured for each scenario according to the different terminology presented. Participant demographics health literacy, 31 cancer worry, 32-35 and general anxiety 36,37 levels (using validated measures) and cancer history were also collected and reported.
Statistical Analysis
Using the Stuart-Maxwell test, 38 we calculated the study to have at least 80% power to detect a difference of at least 5% in the total proportion of participants who chose less invasive treatment when a less serious terminology was used and when the marginal proportions were compared. To simplify this sample size calculation, we assumed that if a participant does not choose surgery (total thyroidectomy or hemithyroidectomy) when a more serious terminology (papillary thyroid cancer) is used, then that participant also would not choose surgery when a less serious description (abnormal cells) is used. Following the formula in Vuolo et al, 38 this assumption resulted in a sample size of 211. We inflated this sample size to account for the multiple comparisons of marginal proportions by setting the significance level for the Stuart-Maxwell test at 0.0167. We doubled this sample size to allow for possible separate subgroup analyses of men and women. To achieve these aims, we recruited 600 participants.
Responses to treatment choice were analyzed across all 3 treatment options and then combined into 2 categories: surgery and active surveillance. Mean anxiety scores were reported numerically. For the first scenario viewed by each participant, analysis of variance was used to compare the mean anxiety scores across the 3 terminologies, and a binary regression model was used to compare the percentage of participants who chose surgery. We investigated whether the order in which terminologies were presented was associated with the proportion of participants who chose surgery and the diagnosis anxiety score by using mixed models that included interactions between terminology and the order of terminology exposure. The data were analyzed using SAS, version 9.4 (SAS Institute). Data analysis was conducted from September 1, 2016, to May 15, 2017.
Results

Participant Characteristics
The sample of 550 participants was broadly representative of the Australian public. Among this group, 279 (50.7%) were women and 269 (48.9%) were men, with a mean (SD) age of 49.9 (15.2) years. Overall, participants were slightly older and had slightly higher levels of educational attainment than the general Australian population, 39 as is typical of health research respondents recruited through the telephone. Fortysix participants (8.4%) reported a diagnosis of cancer (other than thyroid cancer), and more than 50% had at least 1 immediate family member with cancer, which are findings similar to those reported in Australian and international community studies. 40, 41 Participants across the 3 treatment groups were similar in sociodemographic characteristics (Table 1) .
Treatment Choice
The marginal proportion of participants in each of the treatment options differed depending on the terminology used in the case scenarios ( All particpants saw all items across 3 viewings. All participants of the first viewing were then randomized to see the 3 terms in a second viewing and a third viewing. 
Research Original Investigation Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences
When treatment options were dichotomized into surgery (total thyroidectomy or hemithyroidectomy) or active surveillance, a similar association of alternative terminologies with treatment choice was observed, although when the terminologies were viewed first, the differences did not reach statistical significance (Table 3) . At first exposure, the papillary thyroid cancer terminology led 60 of 186 participants (32.3%) to choose surgery compared with 46 of 191 participants (24.1%) who chose surgery after being exposed to the papillary lesion terminology first (risk ratio [RR], 0.73; 95% CI, 0.53-1.02) and 47 of 173 participants (27.2%) after being exposed to abnormal cells (RR, 0.82; 95% CI, 0.60-1.14) terminology first.
Regardless of the terminology used, the overall initial treatment preferences for active surveillance were high (72%) but decreased after the second and third scenarios were presented (66% and 65%, respectively).
Diagnosis Anxiety
We observed the association of the different terminologies with participant-reported anxiety level in response to the diagnosis (Table 4) . Participants reported higher mean anxiety scores when their diagnosis was described as papillary thyroid cancer compared with papillary lesion or abnormal cells across all orders in which the terminology was viewed. After the first exposure, participants who viewed the papillary thyroid cancer terminology reported significantly higher levels of anxiety (mean, 7.8 of 11 points) compared with those who saw the papillary lesion (mean, 7.0 of 11 points; mean difference, -0.8; 95% CI, -1.3 to -0.3) or abnormal cells (mean, 7.3 of 11 points; mean difference, -0.5; 95% CI, -1.0 to 0.01) description. The effect size between the terminologies (Table 4) is similar to the effect size between psychological interventions to manage anxiety after a cancer diagnosis. 42 Adjusting for the covariates had little association with results.
The first, second, and third viewing of papillary thyroid cancer description showed increases in not only the proportion of participants who chose surgery (32.3%, 48.9%, and 54.8%, respectively; Table 3) but also in the level of anxiety in response to the diagnosis (7.8, 8.5, and 8.9 points, respectively; Table 4 ). This increase suggests possible carryover effects of previous descriptions on current outcomes. From the mixed model analysis, there were substantial interactions between terminology and order of terminology viewing in choosing surgery (eTable 2 in Supplement 2) and between terminology and the order of terminology presentation in the diagnosis-related anxiety scores (eTable 3 in Supplement 2).
Treatment Choice Anxiety
Participants who chose surgery reported higher levels of anticipated treatment-related anxiety compared with those who chose active surveillance, regardless of which terminology was seen first (mean difference, 1.5; 95% CI, 1.0-1.9) ( Table 4) .
Discussion
In a hypothetical clinically realistic context, describing PTC without the term cancer led to greater response in nonsurgical options, such as active surveillance, and to lower levels of anxiety. Studies in other indolent tumor types, such as DCIS, also support our findings, demonstrating that describing DCIS without the cancer terminology decreases preferences for surgical treatment and levels of anxiety. 27, 43 Removing the cancer terminology has been proposed for PTC and other lesions with low malignant potential as a strategy for mitigating overdiagnosis and overtreatment, 6, 24 although no studies in this area have been conducted in patient populations or have analyzed the possible long-term risks a Anxiety scores were measured on an 11-point scale with anchored end points ranging from 1 = not anxious at all to 11 = extremely anxious.
b Mean difference, 95% CI, and P values were obtained from analysis of first scenario viewed using analysis of variance.
c Anxiety scores were measured on an 11-point scale with anchored end points ranging from 1 = not anxious at all to 11 = extremely anxious.
d Effect of terminology on treatment choice and on treatment-related anxiety mean difference was 1.5 (95% CI, 1.0-1.9).
e Surgery includes the treatment choice of total thyroidectomy or hemithyroidectomy. and advantages of this change. 44 Changing the terminology of these proposed lesions, however, would not be a straightforward process because cancer is typically defined by pathologic features and behaviors. Therefore, an iterative process that involves all stakeholders may need to be adopted. Noninvasive encapsulated follicular variant of PTC is an example of a condition recently renamed to exclude the term carcinoma and for which a renaming process has been adopted. 45 This change was made to appropriately reflect the biological and clinical characteristics of encapsulated follicular variant of PTC, which rarely exhibits lymph node metastases and behaves indolently. The hope was that the new name would ultimately reduce the psychological and clinical associations (ie, longterm follow-up) with the diagnosis of cancer. 45, 46 We found that the order in which participants were exposed to different PTC terminology might affect treatment decision making and psychological outcomes. Across all 3 scenarios, the association of the terminology used in the description with later exposures increased; that is, those who saw the terminology at the second or third viewing compared with those who read it at the first viewing had significantly higher preferences for surgery and levels of anxiety. This important finding suggests that there may be anchoring, a cognitive bias that occurs during decision making. 47 Participants who did not see "cancer" the first time based their initial judgments on treatment choice and anxiety on the condition called papillary lesion or abnormal cells. They adjusted their judgment later when they saw the condition called papillary thyroid cancer. In a real-world context, patients have numerous consultations with different clinicians as well as receive and read information about their diagnostic pathway from a variety of sources. Encountering a different terminology or description for cancer after a diagnosis may, therefore, alter their perceptions of and reactions to the diagnosis. This finding emphasizes the need for all clinicians in the cancer pathway to agree on and implement this terminology change. Interest in active surveillance, independent from terminology, was high (approximately 70%) even when participants were not specifically told that they could proceed to surgery later, as would be the case in clinical practice. Hypothetical studies on DCIS, in which active surveillance is not currently a standard management option (similar to PTC), have shown the proportion of women interested in active surveillance is high. 27, 43, 48 This interest level among a healthy sample is encouraging and supports previous reports that patients tend to make more conservative treatment decisions after an unbiased presentation of options. Further qualitative (eg, patient interviews) and quantitative (eg, discrete choice experiments) investigations would help identify the factors in patients' treatment decisions, including the terminology used to describe the condition and the trade-offs between treatment risks and advantages that patients may be willing to accept.
Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences
Limitations
The study was limited by its hypothetical framework to understand how people with a real diagnosis of PTC may respond to the scenarios presented to study participants without such a diagnosis. Using this design, however, allowed us to include participants who were unbiased by previous knowledge and information about PTC. Testing people with a PTC diagnosis may not be as meaningful because their responses would be biased by their previous or current experiences, including treatment decision making, and by the terminologies used by their clinicians. We also presented standardized outcomes in the scenarios. In reality, these outcomes may vary by age, comorbidities, surgeon experience, and other factors. However, these outcomes were informed by the best available evidence. Furthermore, the sample was slightly more educated and older than the general Australian population. Recent evidence from US studies, however, suggests that individuals with higher socioeconomic status are more likely to receive a PTC diagnosis.
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Conclusions
This study indicates that, in a hypothetical context, calling a diagnosis cancer does matter. Participants with no previous history of PTC had more interest in active surveillance and lower levels of anxiety when PTC was described without the term cancer and with substitute terminologies lesion and abnormal cells. Our findings support the recommendation to change the terminology for small low-risk PTCs to mitigate the problem of overdiagnosis and overtreatment in this condition. 6, 24 In addition, the findings suggest that the order in which the terminology was presented may be a factor in participant decisions. Furthermore, interest in active surveillance to manage a diagnosis of PTC may be higher than previously anticipated, notably when the risks and advantages of alternative therapies were presented together, allowing individuals to directly compare treatment aspects important to them. Clinicians who manage patients with PTC should ensure that the diagnosis is described consistently and the treatment options are well presented to help reduce anxiety and allow for consideration of less invasive management approaches. The Evolving Nomenclature of Thyroid Cancer What's in a Name?
Independent UK Panel on Breast Cancer
Andrew G. Shuman, MD "Cancer is a word, not a sentence," acknowledged John Diamond 1 as he embarked on an ultimately losing fight with oral carcinoma. It reflects the fear that the word cancer has instilled in the public for millennia. To many, a cancer diagnosis was, and remains, akin to a death sentence or, at the very least, a jarring call to battle. This connotation is rooted in the long-established theory of linguistic relativism, which stipulates that thought and action are determined a priori by language itself.
2 Even today, our nuanced understanding of cancer biology and the inherent diversity of malignant processes has not erased the stigma and terror that the word evokes in our patients. From this background emerges the budding acceptance of the concept of overdiagnosis within the domains of oncology. No longer are indolent cancers necessarily something to be feared and aggressively extirpated but rather to be viewed as objects for observation or, at the least, less aggressive treatment. As with all paradigm shifts, clinicians and patients should adjust practices and expectations deliberately, as the needle slowly inches toward treatment de-escalation. Just as practice and perspective needs to evolve, so, perhaps, does our language.
In 2014, a National Cancer Institute working group boldly suggested the adoption of the term indolent lesion of epithelial origin or IDLE "for those lesions (currently labeled as cancers) and their precursors that are unlikely to cause harm if they are left untreated."
3 The foundation for this conceptual shift is rooted in the hypothesis that the word cancer itself can be so terrifying that it may prompt overtreatment despite counseling based on data suggesting otherwise. This calls into question what truly defines a neoplasm as a cancer; is it a biological potential for progression, a histological appearance, a genomic signature, or a cohesive permutation thereof? Recently, a subset of noninvasive thyroid neoplasms was reclassified to be more consistent with its lack of observed progression or spread. 4 Although this is gratifying and a meaningful change in the literature, it does not address most low-risk, well-differentiated thyroid cancers that have minuscule potential for life-threatening progression but are, histologically at least, still consistent with the contemporary definition of carcinoma.
Redefining terms may correlate with the evolution in management as well. Active surveillance of low-risk papillary microcarcinomas is not new, and a long-term follow-up study in Japan confirms the safety and practicality of this approach among carefully selected patients.
5 Follow-up studies confirm the replicability in American patients. 6 However, active surveillance is not synonymous with doing nothing and requires diligent follow-up, committed multidisciplinary teams, clear language and expectations, and expert ultrasonographers and radiologists. As a result, active surveillance of low-risk papillary microcarcinomas has yet to be fully embraced, until the test of time proves the approach's feasibility and transferability to a wider cadre of centers and practitioners. In addition, the social barriers to this paradigm are formidable, including the pervasive fear and lack of education within the community as well as the counterintuitive stigma of having a so-called good cancer, which can be simultaneously reassuring and troubling. 7 This stigma is reflected not only in patient understanding; clinicians are similarly reticent to de-escalate treatment for a disease that has overall excellent outcomes and a time-tested surgical approach. 
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Interventional
Description of intervention(s) / exposure
The intervention will test how di erent terminologies used to describe the same diagnosis (papillary thyroid cancer) a ect decision making about treatment. This will be done by surveying a population from the Australian community with no history of thyroid cancer and presenting them with 3 hypothetical scenarios that describe a diagnosis of papillary thyroid cancer using various terminology with and without the "cancer" term. The terms presented to participants are papillary thyroid cancer, papillary lesions of indolent course and abnormal cells. Participants will also be given a table with information on the risks and bene ts to each treatment option (total thyroidectomy, hemi-thyroidectomy or active surveillance) so that participants are able to make an informed decision about their treatment options. Each hypothetical scenario and the treatment options presented to participants will be identical with the only di erence being the terminology used.
Participants will be called randomly using random-digit dialing to mobile numbers across Australia by an experienced independent social research company (the Hunter Research Foundation). Participants who agree to participate will be sent a link via email to the online survey. Participants will then complete the survey which includes all 3 hypothetical scenarios at once. It is estimated to take participants 10-15 minutes to complete.
The aim of this intervention is to assess if the term "cancer" used to describe a diagnosis of papillary thyroid cancer may impact patient treatment preferences (primary outcomes) as well as psycho-social outcomes (secondary outcomes).
Intervention code [1]
Treatment: Other
Comparator / control treatment The comparator will be the treatment preference choice. We will be comparing the proportion that
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Intervention code [1] Treatment: Other
Comparator / control treatment The comparator will be the treatment preference choice. We will be comparing the proportion that choose each treatment option under the two descriptions (cancer term included -papillary thyroid cancer vs. no cancer term included -papillary lesions of indolent course or abnormal cells).
Control group
Active
Outcomes
Primary outcome [1] The primary outcome is treatment decision making. This will be measured for each scenario with di erent terminology presented by participants selecting between 3 treatment options (thyroidectomy, hemi-thyroidectomy, active surveillance).
Timepoint [1]
Immediately following intervention (5-10 minutes after participants are presented with the hypothetical diagnosis scenario).
Secondary outcome [1]
Diagnosis-related anxiety. Measured using a 1-item Visual Analog Scale. 
Timepoint [1]
Immediately following intervention (approximately 5 minutes after participants are presented with the hypothetical diagnosis scenario).
Secondary outcome [2]
Treatment-related anxiety. Measured using a 1-item Visual Analog Scale. 
Timepoint [2]
Secondary outcome [3]
General anxiety. Measured using the State-Trait Anxiety Inventory, 
Timepoint [3]
Immediately following intervention (10-15 minutes after participants are presented with the hypothetical diagnosis scenario).
Secondary outcome [4]
Cancer worry. Measured using a 4-point Likert scale. 
Timepoint [4]
Immediately following intervention (10-15 minutes after participants are presented with the hypothetical diagnosis scenario). 
Timepoint [5]
Secondary outcome [6]
Personal/family history of cancer. Multiple choice question.
Timepoint [6]
Eligibility Key inclusion criteria
Participants in this study will be men and women across the Australian community identi ed through random digit dialing. Participants will be eligible to participate in the study if they are above 18 years of age, are uent in English and have no history of a thyroid cancer diagnosis. Researchers will try and recruit a 1:1 ratio of male and female participants.
Minimum age
Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Participants will be excluded from the study if they are unable to speak adequate English upon initial contact, if they do not have a valid email address to access the survey, are below the age of 18 years and have been diagnosed with thyroid cancer.
Study design
Purpose of the study Treatment and have been diagnosed with thyroid cancer.
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by phone. Once a participant agrees to take part in the study they will be randomly assigned to be immediately sent one of the versions of the survey.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computerised sequence generation will be used. An independent research organisation (the Hunter Research Foundation) will use their software to administer the randomisation.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded? The people receiving the treatment/s
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
E cacy
Statistical methods / analysis
The sample size was calculated by simplifying the assumption that if a person does not opt for surgical treatment (active surveillance) when a more serious description is used (ie. papillary thyroid cancer) they will also not opt for surgical intervention when a less serious description is used (ie. abnormal cells) Since we are carrying out multiple comparisons (3 terms analysed separately using McNemar's test, alpha=0.05/3=0.01667) we would need 264 participants to detect a 5% change. We also want to analyse men and women separately therefore, we would need 264 men and 264 women (aim to recruit 600 participants total).
Data will be analysed using chi-square tests to compare the treatment choices (primary outcome) between study arms. A univariate analysis of factors (secondary outcomes and demographic characteristics) associated with surgical treatment choice will be used. A multivariate logistic regression model will also be used to assess predictors of surgical treatment choice by terminology used, including diagnosis and treatment related anxiety, general anxiety, cancer worry, health literacy and personal/family history of cancer.
.All data will be analysed by researchers at the University of Sydney and compiled for publication and dissemination. Approval date [1] 08/12/2015
Recruitment
Ethics approval number [1] 2015/916
Summary Brief summary
Purpose of the study: This study aims to explore how adults with no history of thyroid cancer would make decisions about treatments based on the terminology used to describe a hypothetical diagnosis of papillary thyroid cancer.
Who is it for?: You may be eligible to join this study if you are aged 18 years or more, have no history of thyroid cancer.
Study details: All participants in this study will be presented with three hypothetical scenarios that describe the diagnosis of papillary thyroid cancer using various terminology with and without the "cancer" term. The order in which these scenarios will be provided is random (by chance). Each hypothetical scenario and the treatment options presented to participants will be identical with the only di erence being the terminology used. Following presentation with these scenarios participants will be assessed on treatment preferences and psycho-social outcomes. This research study will contribute to a new body of research aimed at understanding how di erent terminology for precancerous conditions or early stage cancer a ect patient's decision making about treatment. Bold values indicate a significant difference p=0.0074 for interaction between terminology and time viewed
